UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4480-4484

2010

Volltextzugriff (PDF)

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials

JNCI : Journal of the National Cancer Institute, 2009-02, Vol.101 (4), p.248-255

2009

Volltextzugriff (PDF)

Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)

Chest, 2023-02, Vol.163 (2), p.407-418

2023

Volltextzugriff (PDF)

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta- analysis of Randomized Trials

JNCI : Journal of the National Cancer Institute, 2011-12, Vol.103 (23), p.1799-1806

2011

Volltextzugriff (PDF)

Potential Influence of the Anesthetic Technique Used during Open Radical Prostatectomy on Prostate Cancer-related Outcome: A Retrospective Study

Anesthesiology (Philadelphia), 2010-09, Vol.113 (3), p.570-576

2010

Volltextzugriff (PDF)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Respiratory research, 2021-02, Vol.22 (1), p.34-9, Article 34

2021

Volltextzugriff (PDF)

Novel clinical trial designs for targeted therapies

International journal of clinical pharmacology and therapeutics, 2017-08, Vol.55 (8), p.695-697

Hsu Schmitz, Shu-Fang

2017

Volltextzugriff (PDF)

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)

British journal of haematology, 2015-01, Vol.168 (1), p.145-148

2015

Volltextzugriff (PDF)

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

Oncotarget, 2016-06, Vol.7 (25), p.37680-37692

2016

Volltextzugriff (PDF)

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1752-1759

2003

Volltextzugriff (PDF)

Prevention of Docetaxel‐ or Paclitaxel‐Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo‐Controlled, Double‐Blind Study

The oncologist (Dayton, Ohio), 2008-03, Vol.13 (3), p.337-346

2008

Volltextzugriff (PDF)

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Lung cancer (Amsterdam, Netherlands), 2013-01, Vol.79 (1), p.59-64

2013

Volltextzugriff (PDF)

Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)

Journal of clinical oncology, 2005-02, Vol.23 (4), p.705-711

2005

Volltextzugriff (PDF)

Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)

Breast (Edinburgh), 2014-06, Vol.23 (3), p.244-249

2014

Volltextzugriff (PDF)

A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas

Leukemia & lymphoma, 2014-06, Vol.55 (6), p.1288-1294

2014

Volltextzugriff (PDF)

Design choices for small-scale phase II trials with non-inferiority (NI) intention

Trials, 2011-12, Vol.12 (Suppl 1), p.A89-A89

2011

Volltextzugriff (PDF)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

Advances in therapy, 2022-01, Vol.39 (1), p.796-810

2022

Volltextzugriff (PDF)

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC

BMC palliative care, 2012-09, Vol.11 (1), p.19-19, Article 19

2012

Volltextzugriff (PDF)

A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials

Contemporary clinical trials, 2009-05, Vol.30 (3), p.201-204

2009

Volltextzugriff (PDF)

Homeopathic treatment of children with attention deficit hyperactivity disorder : a randomised, double blind, placebo controlled crossover trial

European journal of pediatrics, 2005-12, Vol.164 (12), p.758-767

2005

Volltextzugriff (PDF)

Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

British journal of haematology, 2004-02, Vol.124 (3), p.289-298

2004

Volltextzugriff (PDF)

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9044-9044

2016

Volltextzugriff (PDF)

The Influence of Treatment- and Vaccination-induced Changes in the Risky Contact Rate on HIV Transmission

Mathematical population studies, 2007-01, Vol.14 (1), p.57-76

HSU SCHMITZ, SHU-FANG

2007

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Englisch
(59)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Humans
(28)
Oncology
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Middle Aged
(13)
Aged
(12)
Female
(12)
Male
(12)
Treatment Outcome
(12)
Adult
(9)
Antineoplastic Agents - Therapeutic Use
(9)
Rituximab
(8)
Disease-Free Survival
(7)
Lymphoma, Follicular - Drug Therapy
(7)
Neoplasm Staging
(7)
Tumors
(7)
Antineoplastic Agents - Administration & Dosage
(6)
Drug Administration Schedule
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials

Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta- analysis of Randomized Trials

Potential Influence of the Anesthetic Technique Used during Open Radical Prostatectomy on Prostate Cancer-related Outcome: A Retrospective Study

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Novel clinical trial designs for targeted therapies

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial

Prevention of Docetaxel‐ or Paclitaxel‐Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo‐Controlled, Double‐Blind Study

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)

Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)

A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas

Design choices for small-scale phase II trials with non-inferiority (NI) intention

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC

A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials

Homeopathic treatment of children with attention deficit hyperactivity disorder : a randomised, double blind, placebo controlled crossover trial

Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M

The Influence of Treatment- and Vaccination-induced Changes in the Risky Contact Rate on HIV Transmission

Suchergebnisse filtern